Phreesia (PHR) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
30 Jun, 2026Opening remarks and agenda
The meeting was called to order by the CEO, who welcomed stockholders and visitors and outlined the agenda and rules of conduct for the virtual meeting.
Directors, officers, independent auditors, and outside counsel were introduced at the start of the meeting.
The meeting was held in accordance with company bylaws and Delaware law, with formal business as described in the notice and proxy statement.
Board and executive committee updates
The board consists of nine directors, and key officers including the CFO, Presidents of Provider and Network Solutions, General Counsel, and SVP of HR were present.
Shareholder proposals
Three proposals were presented: election of two Class I directors for a three-year term, ratification of KPMG as independent auditor for FY ending January 31, 2027, and a non-binding advisory vote on executive compensation for FY 2026.
No stockholder nominations for directors were received in advance.
Latest events from Phreesia
- Q1 FY2027 revenue up 13%, net income $3M, and FY2027 guidance reaffirmed.PHR
Q1 2027 - Proxy seeks approval for director elections, auditor ratification, and executive pay, highlighting governance and ESG.PHR
Proxy filing - Key votes include director elections, auditor ratification, and executive pay approval.PHR
Proxy filing - FY27 revenue guidance lowered on pharma headwinds, but margin and cash flow outlooks remain strong.PHR
Q4 2026 - Q3 FY2026 saw 13% revenue growth, profitability, and a major acquisition completed.PHR
Q3 2026 - Annual meeting to vote on directors, auditor, and executive pay, with focus on governance and ESG.PHR
Proxy Filing - Revenue up 17%, net loss narrowed, and Adjusted EBITDA positive with strong outlooks ahead.PHR
Q3 2025 - Revenue up 19%, net loss halved, and positive free cash flow achieved in Q2 FY25.PHR
Q2 2025 - Double-digit revenue growth, positive cash flow, and strong 2026 outlook maintained.PHR
Q4 2025